Physician review
Prescription decisions begin with medical-history and contraindication review by Dr. Anjmun Sharma, MD.
Not all weight loss injections are equal. Here's what actually works, what's hype, and how New Hope Weight Loss combines prescription GLP-1 therapy with optional metabolic support, a non-surgical, telehealth weight loss program under Dr. Sharma's care.

Prescription GLP-1 injections can support weight management for some eligible adults. New Hope may consider compounded semaglutide or tirzepatide after physician review. Compounded medications are not FDA-approved or brand-identical, and results vary. The published physician review is $119; medication is billed separately, and location availability is confirmed during consultation.
Important: Compounded semaglutide and tirzepatide are not FDA-approved and are not brand-identical. Eligibility and results vary.
Costs less than your daily coffee.
$166 a month, physician-supervised, no insurance needed.
The weight-loss injections with real clinical evidence are the GLP-1 receptor agonists: semaglutide (same ingredient as Wegovy/Ozempic) and tirzepatide (same ingredient as Mounjaro/Zepbound). These are once-weekly self-injections that reduce appetite and food noise at the hormonal level.
STEP 1 and SURMOUNT-1 studied FDA-approved brand products, not compounded preparations. Their results are limited to the product, population, dose, and period studied; they do not predict an individual outcome or an outcome for a compounded preparation. Read the semaglutide and tirzepatide pages to review each option and its limits separately.
For patients who want extra energy support during their program, we offer B12 and lipotropic (MIC) injections as an add-on or included in our Advanced Reset plan. These aren't a substitute for GLP-1 therapy, they complement it for some patients.
"Appetite-control injection" usually refers to GLP-1 medications. They work by signaling fullness and slowing digestion, genuine appetite reduction, not a stimulant. Dr. Sharma screens every patient for contraindications and titrates the dose to keep side effects manageable.
HSA/FSA accepted. No insurance required.
The FDA-approved brand products Wegovy 2.4 mg and Zepbound 15 mg were studied separately in STEP 1 and SURMOUNT-1, with defined populations, doses, and periods. Those approved-product results do not establish outcomes for compounded preparations; they are not FDA-approved or brand-identical, and results vary.
New Hope Weight Loss is in Costa Mesa, CA and provides telehealth care for eligible patients in California. Your consultation and prescription happen online and medication fulfillment is available only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient location, with packaging and shipping details confirmed by the pharmacy before fulfillment, no in-person visit required for most patients.
GLP-1 appetite-control injections work by mimicking a gut hormone that signals fullness and slows digestion. They produce genuine, measurable appetite reduction in clinical trials. They require a prescription and physician supervision.
At New Hope Weight Loss: $119 one-time doctor review, then semaglutide from $166/month or tirzepatide from $233/month. A one-month trial is $199. HSA/FSA accepted; no insurance needed.
From about $5.50 a day, less than a daily latte
A fraction of brand-name GLP-1 list prices, which often run $900 to $1,300 or more a month.
$119 one-time to get started with your physician consultation.
Medical disclaimer: Individual results may vary. GLP-1 medications require a physician prescription and ongoing supervision. Clinical trial results cited are averages; not all patients achieve the same outcomes. Eligibility is determined during the medical consultation. This information does not replace professional medical advice.
New Hope Weight Loss | 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location.